Is DRNA or QYLD a better dividend investment in 2026?

DRNA currently yields 5.23% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: QYLD offers higher current income.

What is the dividend yield difference between DRNA and QYLD?

DRNA has a forward dividend yield of 5.23% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 6.69 percentage points.

Home › Compare › DRNA vs QYLD

DRNA vs QYLD: Dividend Comparison 2026

DRNA yields 5.23% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 DRNA wins by $2.8K in total portfolio value

INVESTMENT

TIME HORIZON10 years

DRNA

● Live price

5.23%

Share price

$38.22

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$28.2K

Annual income

$731.12

Full DRNA calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — DRNA vs QYLD

📍 DRNA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	DRNA	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, DRNA + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

DRNA pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DRNA

Annual income on $10K today (after 15% tax)

$444.79/yr

After 10yr DRIP, annual income (after tax)

$621.45/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, QYLD beats the other by $4,188.96/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DRNA + QYLD for your $10,000?

DRNA: 50%QYLD: 50%

100% QYLD50/50100% DRNA

Portfolio after 10yr

$26.8K

Annual income

$3,195.22/yr

Blended yield

11.92%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on DRNA right now

DRNA

Analyst Ratings

Buy

Hold

Consensus: Buy

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DRNA buys

QYLD buys

No recent congressional trades found for DRNA or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricDRNAQYLD

Forward yield	5.23%	11.92% ✓
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$28.2K ✓	$25.4K
Annual income after 10y	$731.12	$5,659.31 ✓
Total dividends collected	$6.3K	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: DRNA vs QYLD ($10,000, DRIP)

Year	DRNA Portfolio	DRNA Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$11,223	$523.29	$10,352	$1,192.36	+$871.00 → DRNA
2	$12,558	$548.88	$10,830	$1,347.57	+$1.7K → DRNA
3	$14,011	$573.96	$11,460	$1,539.07	+$2.6K → DRNA
4	$15,590	$598.48	$12,275	$1,777.84	+$3.3K → DRNA
5	$17,304	$622.37	$13,323	$2,078.95	+$4.0K → DRNA
6	$19,161	$645.59	$14,667	$2,463.34	+$4.5K → DRNA
7	$21,170	$668.11	$16,396	$2,960.57	+$4.8K → DRNA
8	$23,342	$689.88	$18,631	$3,612.97	+$4.7K → DRNA
9	$25,686	$710.89	$21,548	$4,482.15	+$4.1K → DRNA
10	$28,216	$731.12	$25,398	$5,659.31	+$2.8K → DRNA

DRNA vs QYLD: Complete Analysis 2026

DRNA — Stock

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; belcesiran for the treatment of deficiency-associated liver disease; and DCR-AUD for the treatment of alcohol use disorder. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts. As of December 27, 2021, Dicerna Pharmaceuticals, Inc. operates as a subsidiary of Novo Nordisk A/S.

Full DRNA Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this DRNA vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DRNA vs SCHD DRNA vs JEPI DRNA vs O DRNA vs KO DRNA vs MAIN DRNA vs XYLD DRNA vs JEPQ DRNA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.